Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Brief description of study

Primary Objective:

  • To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B

Secondary Objective:

  • To characterize the safety and tolerability
  • To determine fitusiran plasma concentrations at selected time points

The estimated total time on study is up to 160 weeks in participants who roll over into the extension study and up to 184 weeks in participants who do not roll over into the extension study (due to the requirement for up to an additional 6 months of follow-up for monitoring of AT levels).

Clinical Study Identifier: NCT03974113

You may be eligible for this study if you meet the following criteria:

  • Conditions: Hemophilia
  • Age: Between 1 Year - 11 Years
  • Gender: Male

Inclusion criteria :

  • Male, aged 1 to <12 years at the time of enrollment
  • Severe hemophilia A or B (Factor VIII (FVIII) <1% or Factor IX (FIX) ≤2%)
  • Participants must have inhibitory antibodies to FVIII or FIX and must meet one of the following Nijmegen-modified Bethesda assay results criteria:
    • Inhibitor titer of ≥0.6 BU/mL at screening, OR
    • Inhibitor titer of <0.6 BU/mL at screening with medical record evidence of 2 consecutive titers ≥0.6 BU/mL, OR
    • Inhibitor titer of <0.6 BU/mL at screening with medical record evidence of 1 inhibitor titer ≥0.6 BU/mL and a history of anamnestic response or severe allergic reaction (anaphylaxis or nephrotic syndrome)
  • Adequate peripheral venous access, as determined by the Investigator, to allow the

    blood draws required by the study protocol

  • Weight requirements at the time of enrollment: 8 to <45 kg
  • Willing and able to comply with the study requirements and to provide signed written informed consent obtained from parent(s)/legal guardian (hereinafter the "parent") and written or oral assent obtained from participant, per local and national requirements

Exclusion criteria:

  • Known co-existing bleeding disorders other than hemophilia A or B
  • Antithrombin (AT) activity <60% at Screening
  • Co-existing thrombophilic disorder
  • Clinically significant liver disease
  • Active Hepatitis C virus infection
  • Acute or chronic Hepatitis B virus infection
  • Acute Hepatitis A or hepatitis E infection
  • HIV positive with a CD4 count of <400 cells/μL
  • History of arterial or venous thromboembolism, unrelated to an indwelling venous access
  • Inadequate renal function
  • History of multiple drug allergies or history of allergic reaction to an oligonucleotide or N-Acetylgalactosamine (GalNAc)
  • Participants with central or peripheral indwelling catheters, with history of venous access complications leading to hospitalization and/or systemic anticoagulation therapy
  • History of intolerance to subcutaneous (SC) injection(s)
  • The use of emicizumab (Hemlibra®) within 6 months prior to screening
  • Any other conditions or comorbidities that would make the patient unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgment
        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.

Last updated on 08 Apr 2022

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250